Shyam Prabhakaran1, David S Liebeskind2, George Cotsonis3, Azhar Nizam3, Edward Feldmann4, Rajbeer S Sangha5, Iszet Campo-Bustillo6, Jose G Romano6. 1. The University of Chicago, Chicago, IL, USA. Electronic address: shyam1@uchicago.edu. 2. University of California at Los Angeles, Los Angeles, CA, USA. 3. Emory University, Atlanta, GA, USA. 4. The University of Massachusetts Medical School-Baystate, Springfield, MA, USA. 5. University of Alabama at Birmingham, Birmingham, AL, USA. 6. University of Miami, Miami, FL, USA.
Abstract
OBJECTIVES: Hyperlipidemia is a strong risk factor for intracranial atherosclerotic disease (ICAD) and clinical stroke recurrence. We explored the effect of serum lipid levels on subclinical infarct recurrence in the Mechanisms of earlY Recurrence in Intracranial Atherosclerotic Disease (MYRIAD) study. MATERIALS AND METHODS: We included enrolled MYRIAD patients with lipid measurements and brain MRI at baseline and brain MRI at 6-8 weeks. Infarct recurrence was defined as new infarcts in the territory of the symptomatic artery on brain MRI at 6-8 weeks compared to baseline brain MRI. We assessed the association between baseline total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels and recurrent infarct at 6-8 weeks using multivariable logistic regression. RESULTS: Among 74 patients (mean age 64.2±12.9 years, 59.5% were white, 60.8% men), 20 (27.0%) had new or recurrent infarcts. Mean HDL-C (37.2 vs. 43.9 mg/dL, P=0.037) was lower and TG (113.5 vs. 91.3 mg/dL, P=0.008) was higher while TC (199.8 vs. 174.3 mg/dL, P=0.061) and LDL-C (124.3 vs. 101.2 mg/dL, P=0.053) were nominally higher among those with recurrent infarcts than those without. LDL-C (adj. OR 1.022, 95% CI 1.004-1.040, P=0.015) and TG (adj. OR 1.009, 95% CI 1.001-1.016, P=0.021) were predictors of recurrent infarct at 6-8 weeks adjusting for other clinical and imaging factors. CONCLUSIONS: Baseline cholesterol markers can predict early infarct recurrence in patients with symptomatic ICAD. More intensive and rapid lipid lowering drugs may be required to reduce risk of early recurrence.
OBJECTIVES: Hyperlipidemia is a strong risk factor for intracranial atherosclerotic disease (ICAD) and clinical stroke recurrence. We explored the effect of serum lipid levels on subclinical infarct recurrence in the Mechanisms of earlY Recurrence in Intracranial Atherosclerotic Disease (MYRIAD) study. MATERIALS AND METHODS: We included enrolled MYRIAD patients with lipid measurements and brain MRI at baseline and brain MRI at 6-8 weeks. Infarct recurrence was defined as new infarcts in the territory of the symptomatic artery on brain MRI at 6-8 weeks compared to baseline brain MRI. We assessed the association between baseline total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels and recurrent infarct at 6-8 weeks using multivariable logistic regression. RESULTS: Among 74 patients (mean age 64.2±12.9 years, 59.5% were white, 60.8% men), 20 (27.0%) had new or recurrent infarcts. Mean HDL-C (37.2 vs. 43.9 mg/dL, P=0.037) was lower and TG (113.5 vs. 91.3 mg/dL, P=0.008) was higher while TC (199.8 vs. 174.3 mg/dL, P=0.061) and LDL-C (124.3 vs. 101.2 mg/dL, P=0.053) were nominally higher among those with recurrent infarcts than those without. LDL-C (adj. OR 1.022, 95% CI 1.004-1.040, P=0.015) and TG (adj. OR 1.009, 95% CI 1.001-1.016, P=0.021) were predictors of recurrent infarct at 6-8 weeks adjusting for other clinical and imaging factors. CONCLUSIONS: Baseline cholesterol markers can predict early infarct recurrence in patients with symptomatic ICAD. More intensive and rapid lipid lowering drugs may be required to reduce risk of early recurrence.
Authors: Konstantinos C Koskinas; Stephan Windecker; Giovanni Pedrazzini; Christian Mueller; Stéphane Cook; Christian M Matter; Olivier Muller; Jonas Häner; Baris Gencer; Carmela Crljenica; Poorya Amini; Olga Deckarm; Juan F Iglesias; Lorenz Räber; Dik Heg; François Mach Journal: J Am Coll Cardiol Date: 2019-08-31 Impact factor: 24.094
Authors: Deepak L Bhatt; P Gabriel Steg; Michael Miller; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Ralph T Doyle; Rebecca A Juliano; Lixia Jiao; Craig Granowitz; Jean-Claude Tardif; Christie M Ballantyne Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Walter N Kernan; Bruce Ovbiagele; Henry R Black; Dawn M Bravata; Marc I Chimowitz; Michael D Ezekowitz; Margaret C Fang; Marc Fisher; Karen L Furie; Donald V Heck; S Claiborne Clay Johnston; Scott E Kasner; Steven J Kittner; Pamela H Mitchell; Michael W Rich; DeJuran Richardson; Lee H Schwamm; John A Wilson Journal: Stroke Date: 2014-05-01 Impact factor: 7.914
Authors: R L Sacco; R T Benson; D E Kargman; B Boden-Albala; C Tuck; I F Lin; J F Cheng; M C Paik; S Shea; L Berglund Journal: JAMA Date: 2001-06-06 Impact factor: 56.272
Authors: Hugh S Markus; Dirk W Droste; Manfred Kaps; Vincent Larrue; Kennedy R Lees; Mario Siebler; E Bernd Ringelstein Journal: Circulation Date: 2005-04-25 Impact factor: 29.690
Authors: Xin Wang; Wen Hua Lin; Yu Dong Zhao; Xiang Yan Chen; Thomas W Leung; Christopher Chen; Jianhui Fu; Hugh Markus; Qing Hao; Ka Sing Wong Journal: Int J Stroke Date: 2012-08-07 Impact factor: 5.266
Authors: Tanya N Turan; Azhar Nizam; Michael J Lynn; Brent M Egan; Ngoc-Anh Le; Maria F Lopes-Virella; Kathie L Hermayer; Jamie Harrell; Colin P Derdeyn; David Fiorella; L Scott Janis; Bethany Lane; Jean Montgomery; Marc I Chimowitz Journal: Neurology Date: 2016-12-21 Impact factor: 9.910
Authors: Victor J Del Brutto; David S Liebeskind; Jose G Romano; Iszet Campo-Bustillo; George Cotsonis; Azhar Nizam; Shyam Prabhakaran Journal: J Stroke Cerebrovasc Dis Date: 2021-06-30 Impact factor: 2.677